» Articles » PMID: 19914960

Prognostic Value of 18F-FDG PET/CT Before and After Radiotherapy for Locally Advanced Nasopharyngeal Carcinoma

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2009 Nov 17
PMID 19914960
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The purpose of this study was to evaluate the prognostic value of maximal standard uptake values (SUVs(max)) from serial fluor-18-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in patients with locally advanced nasopharyngeal carcinoma (NPC).

Materials And Methods: From October 2002 to January 2004, 62 patients with locally advanced NPC who underwent (18)F-FDG PET/CT scan before and after radiotherapy were reviewed retrospectively. We examined the association of SUV(max) and the results of long-term follow-up of the patients.

Results: Patients having tumors with a lower SUV(max) had significantly better 5-year overall survival (OS) (P= 0.0187) and disease-free survival (DFS) (P = 0.0163) than patients with a greater SUV(max). The patients who showed with metabolic complete response had a significantly higher 5-year OS (P = 0.0237) and DFS (P = 0.0186) than patients with metabolic partial response. Poor prognosis was found in patients with the SUV(max) of neck nodes larger than that at the primary tumor site (SUV(max-N) > SUV(max-P)) (P = 0.0440).

Conclusions: (18)F-FDG uptake, as measured by the SUV(max) before radiotherapy and metabolic response after radiotherapy, may predict the prognosis in locally advanced NPC. High (18)F-FDG uptake before and after radiotherapy may be useful for identifying patients requiring more aggressive treatment.

Citing Articles

Radiomics-clinical nomogram based on pretreatment 18F-FDG PET-CT radiomics features for individualized prediction of local failure in nasopharyngeal carcinoma.

Ding J, Li Z, Lin Y, Huang C, Chen J, Hong J Sci Rep. 2023; 13(1):18167.

PMID: 37875498 PMC: 10598204. DOI: 10.1038/s41598-023-44933-7.


Prognostic value of pre-treatment FDG PET/CT SUVmax for metastatic lesions in de novo metastatic nasopharyngeal carcinoma following chemotherapy and locoregional radiotherapy.

Yan W, Sun C, Ou X, Hu C Cancer Imaging. 2023; 23(1):21.

PMID: 36829263 PMC: 9960210. DOI: 10.1186/s40644-023-00536-z.


Prospective Investigation of FDG-PET/MRI with Intravoxel Incoherent Motion Diffusion-Weighted Imaging to Assess Survival in Patients with Oropharyngeal or Hypopharyngeal Carcinoma.

Chan S, Yeh C, Ng S, Lin C, Wang J, Chang J Cancers (Basel). 2022; 14(24).

PMID: 36551590 PMC: 9775681. DOI: 10.3390/cancers14246104.


The role of PET/CT in radiotherapy for nasopharyngeal carcinoma.

Li H, Kong Z, Xiang Y, Zheng R, Liu S Front Oncol. 2022; 12:1017758.

PMID: 36338692 PMC: 9634754. DOI: 10.3389/fonc.2022.1017758.


Pretreatment [F]FDG PET/CT and MRI in the prognosis of nasopharyngeal carcinoma.

Gihbid A, Cherkaoui Salhi G, Alami I, Belgadir H, Tawfiq N, Bendahou K Ann Nucl Med. 2022; 36(10):876-886.

PMID: 35836088 DOI: 10.1007/s12149-022-01770-4.